## ORAL ABSTRACT SESSIONS

<table>
<thead>
<tr>
<th>Abstract title</th>
<th>IU authors: presenter names are bold</th>
<th>Date/time</th>
<th>Abstract</th>
<th>Abstract link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).</td>
<td>Nabil Adra</td>
<td>June 1, 2024; 3 p.m. – 6 p.m. CDT</td>
<td>LBA5000</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/234591">https://meetings.asco.org/abstracts-presentations/234591</a></td>
</tr>
<tr>
<td>Risk prediction model for taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane therapy: SWOG S1714.</td>
<td>Bryan P. Schneider</td>
<td>June 2, 2024; 8 a.m. – 11 a.m. CDT</td>
<td>12005</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233442">https://meetings.asco.org/abstracts-presentations/233442</a></td>
</tr>
<tr>
<td>Primary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial.</td>
<td>Kurt Kroenke</td>
<td>June 2, 2024; 8 a.m. – 11 a.m. CDT</td>
<td>LBA12006</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/234537">https://meetings.asco.org/abstracts-presentations/234537</a></td>
</tr>
<tr>
<td>A multicenter analysis evaluating educational resources utilized by hematology/oncology fellows (HOF).</td>
<td>Fadi Taza</td>
<td>June 3, 2024; 9:45 a.m. – 11:15 a.m. CDT</td>
<td>9003</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/231743">https://meetings.asco.org/abstracts-presentations/231743</a></td>
</tr>
<tr>
<td>ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.</td>
<td>Tarah J. Ballinger, Kathy Miller, Bryan P. Schneider</td>
<td>June 3, 2024; 3 p.m. – 6 p.m. CDT</td>
<td>LBA503</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/232423">https://meetings.asco.org/abstracts-presentations/232423</a></td>
</tr>
</tbody>
</table>

## EDUCATION SESSIONS/PANELS

<table>
<thead>
<tr>
<th>Session title</th>
<th>Panelist</th>
<th>Date/time</th>
<th>Session detail</th>
<th>Session link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-Centered Care and Advances in the Treatment of Testis and Penile Cancer: &quot;Long-Term Survivorship and Treatment Deintensification in Testis Cancer&quot;</td>
<td>Lois Travis</td>
<td>May 31, 2024, 2:45 p.m. – 4:00 p.m. CDT</td>
<td>Education session</td>
<td><a href="https://meetings.asco.org/2024-asco-annual-meeting/15717?presentation=228467#228467">https://meetings.asco.org/2024-asco-annual-meeting/15717?presentation=228467#228467</a></td>
</tr>
<tr>
<td>A Multidisciplinary Approach to Managing the Toxicities Associated With Renal Cell Carcinoma Therapy</td>
<td>Suparna Chandra Clasen</td>
<td>June 3, 2024; 4:45 p.m. – 5:45 p.m. CDT</td>
<td>Case-based panel</td>
<td><a href="https://meetings.asco.org/2024-asco-annual-meeting/15735?presentation=228520#228520">https://meetings.asco.org/2024-asco-annual-meeting/15735?presentation=228520#228520</a></td>
</tr>
</tbody>
</table>

## POSTER SESSIONS

<table>
<thead>
<tr>
<th>Abstract title</th>
<th>IU authors: presenter names are bold</th>
<th>Date/time</th>
<th>Abstract number, poster number</th>
<th>Abstract link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serial testing to assess cognitive function in patients with cancer being treated with immunotherapy.</td>
<td>Shobha Shahani, Ali Ajrouch, Nasser Hanna</td>
<td>June 1, 2024; 9 a.m. – 12 p.m. CDT</td>
<td>Abstract #TPS1644; Poster #512a</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/235283">https://meetings.asco.org/abstracts-presentations/235283</a></td>
</tr>
<tr>
<td>Disparities in breast cancer prevention initiatives at a comprehensive cancer center: Who are we serving?</td>
<td>Tarah Ballinger</td>
<td>June 1, 2024; 9 a.m. – 12 p.m. CDT</td>
<td>Abstract #1615; Poster #486</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233764">https://meetings.asco.org/abstracts-presentations/233764</a></td>
</tr>
<tr>
<td>A phase 2 clinical trial of first-in-class fascin inhibitor NP-Q2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.</td>
<td>Shadis Jalal</td>
<td>June 1, 2024; 9 a.m. – 12 p.m. CDT</td>
<td>Abstract #3112; Poster #257</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/234082">https://meetings.asco.org/abstracts-presentations/234082</a></td>
</tr>
<tr>
<td>Facilitating adaptive coping with fear of recurrence among breast cancer survivors: Feasibility and acceptability outcomes from a three-arm randomized controlled trial.</td>
<td>Shelley Johns, Kathy Miller</td>
<td>June 1, 2024; 9 a.m. – 12 p.m. CDT</td>
<td>Abstract #1630; Poster #501</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233696">https://meetings.asco.org/abstracts-presentations/233696</a></td>
</tr>
<tr>
<td>Exploring health disparities in prostate cancer through circulating tumor DNA analysis.</td>
<td>Samanah Malekina, Nabil Adra, Reza Shahbazi</td>
<td>June 1, 2024; 9 a.m. – 12 p.m. CDT</td>
<td>Abstract #1603; Poster #474</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233719">https://meetings.asco.org/abstracts-presentations/233719</a></td>
</tr>
<tr>
<td>Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.</td>
<td>Greg Durm</td>
<td>June 1, 2024; 9 a.m. – 12 p.m. CDT</td>
<td>Abstract #2524; Poster #3</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233884">https://meetings.asco.org/abstracts-presentations/233884</a></td>
</tr>
<tr>
<td>A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.</td>
<td>Mateusz Opychal</td>
<td>June 1, 2024; 9 a.m. – 12 p.m. CDT</td>
<td>Abstract #2623; Poster #102</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233991">https://meetings.asco.org/abstracts-presentations/233991</a></td>
</tr>
<tr>
<td>Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma.</td>
<td>Melissa Bear</td>
<td>June 1, 2024; 1:30 p.m. – 4:30 p.m. CDT</td>
<td>Abstract #10033; Poster #400</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/235983">https://meetings.asco.org/abstracts-presentations/235983</a></td>
</tr>
</tbody>
</table>
Naxitramab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.

Melissa Bear  
June 1, 2024; 1:30 p.m. – 4:30 p.m. CDT  
Abstract #10032; Poster #399  
https://meetings.asco.org/abstracts-presentations/230982

Genomic signature analysis and survival outcomes in cholangiocarcinoma (CCA) using oncology research information exchange network (ORIEN) database.

Anita Turk, Ashiq Masood  
June 1, 2024; 1:30 p.m. – 4:30 p.m. CDT  
Abstract #4101; Poster #81  
https://meetings.asco.org/abstracts-presentations/234270

QUIC: Phase 2 study of germline/ab, cisplatin, quinolol/carboplatin (AB680D) and zimberitamib (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-56A.

Anita Turk  
June 1, 2024; 1:30 p.m. – 4:30 p.m. CDT  
Abstract #TPS4195; Poster #167b  
https://meetings.asco.org/abstracts-presentations/230948

Longitudinal evaluation of circulating tumor DNA (ctDNA) as a prognostic biomarker to detect minimal residual disease (MRD) in testicular cancer.

Rebecca Hassoun, Clint Cary, Timothy Masterson, Jennifer King, Lawrence Einhorn, Nabil Adra  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #5034; Poster #352  
https://meetings.asco.org/abstracts-presentations/234447

Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.

Ahmed Bilal Khalid, Tareq Salous, Clint Cary, Timothy Masterson, Lawrence Einhorn, Nabil Adra, Jennifer King  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #5035; Poster #353  
https://meetings.asco.org/abstracts-presentations/234453

Management of progressive brain metastases in patients (pts) with relapsed germ-cell tumor (GCT) treated with salvage high-dose chemotherapy (HDCT).

Jennifer King, Rafat Abouour, Tareq Salous, Nasser Hanna, Lawrence Einhorn, Nabil Adra  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #5036; Poster #354  
https://meetings.asco.org/abstracts-presentations/234455

Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma.

Clint Cary  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #5037; Poster #355  
https://meetings.asco.org/abstracts-presentations/238814


Nabil Adra  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #5042; Poster #448  
https://meetings.asco.org/abstracts-presentations/234506

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage I, HR+, HER2-, RS ≤18 breast cancer.

Richard Zellars  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #TP5622; Poster #208b  
https://meetings.asco.org/abstracts-presentations/238854

A phase II trial of sildenafil plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (cRCC).

Nabil Adra  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #5452; Poster #237  
https://meetings.asco.org/abstracts-presentations/234391

Unraveling the gene expression signatures with associated clinical outcomes in papillary renal cell carcinoma.

Jennifer King  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #4558; Poster #253  
https://meetings.asco.org/abstracts-presentations/234036

Advanced renal cell cancer combination immunotherapy clinical trial (ARCITIZE; HCRN GU 22-587).

Jennifer King  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #TPS4194; Poster #305b  
https://meetings.asco.org/abstracts-presentations/238451

Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.

Kathy Miller  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #555; Poster #147  
https://meetings.asco.org/abstracts-presentations/233453

RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).

Anna Maria Storniolo  
June 2, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #5630; Poster #122  
https://meetings.asco.org/abstracts-presentations/233453

Improved survival for myeloid malignancy patients receiving thiopeta/cyclophosphamide (TT/Cy) versus total body irradiation/cyclophosphamide (TBI/Cy) conditioning and allogeneic stem cell transplantation.

Cydney Nichols, Jennifer Schwartz, Michael Robertson, Rafat Abouour  
June 3, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #6555; Poster #114  
https://meetings.asco.org/abstracts-presentations/232600

Comparison of the clinical and genomic profiles of endometrial cancer in Appalachian and non-Appalachian patients.

Lisa Landrum  
June 3, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #5591; Poster #462  
https://meetings.asco.org/abstracts-presentations/234550

Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with doxorubicin plus chemotherapy in the RUBY trial.

Lisa Landrum  
June 3, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #5606; Poster #477  
https://meetings.asco.org/abstracts-presentations/234678

Thiopeta/cyclophosphamide (TT/Cy) preparative regimen for patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation.

Cydney Nichols, Jennifer Schwartz, Michael Robertson, Rafat Abouour  
June 3, 2024; 9 a.m. – 12 p.m. CDT  
Abstract #6566; Poster #114  
https://meetings.asco.org/abstracts-presentations/232610

Comprehensive molecular characterization of thymic epithelial tumors.

Patrick Loehrer, Rohan Maniar  
June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT  
Abstract #8113; Poster #375  
https://meetings.asco.org/abstracts-presentations/232836

Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: 2024 update of a model for remote clinical trial participation.

Brenna McDonald  
June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT  
Abstract #TPS12147; Poster #275b  
https://meetings.asco.org/abstracts-presentations/238569

A phase II trial of mizuolumab in combination with durvalumab (MED14736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART); Hoosier Cancer Research Network LUN21-530 study.

Misty Shields, Shadia Jalal  
June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT  
Abstract #TPS8129; Poster #364a  
https://meetings.asco.org/abstracts-presentations/238527

A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I nonsmall cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-133.

Greg Durm, Nasser Hanna  
June 3, 2024; 1:30 p.m. – 4:30 p.m. CDT  
Abstract #TPS8118; Poster #378b  
https://meetings.asco.org/abstracts-presentations/238538
<table>
<thead>
<tr>
<th>Abstract title</th>
<th>IU authors</th>
<th>June 3, 2024: 9 a.m. – 12 p.m. CDT</th>
<th>Abstract #11088</th>
<th>Poster #303</th>
<th><a href="https://meetings.asco.org/abstracts-presentations/233246">https://meetings.asco.org/abstracts-presentations/233246</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Proactive, automated monitoring of uncontrolled symptoms in prostate cancer survivors across the cancer control continuum.</td>
<td>Kurt Kroenke</td>
<td>June 3, 2024: 1:30 p.m. – 4:30 p.m. CDT</td>
<td>Abstract #12079</td>
<td>Poster #208</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233364">https://meetings.asco.org/abstracts-presentations/233364</a></td>
</tr>
<tr>
<td>Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial.</td>
<td>Kurt Kroenke</td>
<td>June 3, 2024: 1:30 p.m. – 4:30 p.m. CDT</td>
<td>Abstract #12065</td>
<td>Poster #194</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233400">https://meetings.asco.org/abstracts-presentations/233400</a></td>
</tr>
<tr>
<td>Formation and evaluation of the ASCO medical education community of practice (Med Ed CoP).</td>
<td>Jennifer Schwartz</td>
<td>June 3, 2024: 1:30 p.m. – 4:30 p.m. CDT</td>
<td>Abstract #9022</td>
<td>Poster #11</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/232898">https://meetings.asco.org/abstracts-presentations/232898</a></td>
</tr>
<tr>
<td>A meta-analysis GWAS of taxane-induced peripheral neuropathy in patients with breast cancer.</td>
<td>Bryan P. Schneider</td>
<td>June 3, 2024: 1:30 p.m. – 4:30 p.m. CDT</td>
<td>Abstract #12089</td>
<td>Poster #218</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/231310">https://meetings.asco.org/abstracts-presentations/231310</a></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Abstract title</th>
<th>IU authors</th>
<th>June 3, 2024: 1:30 p.m. – 4:30 p.m. CDT</th>
<th>Abstract #16276</th>
<th><a href="https://meetings.asco.org/abstracts-presentations/235071">https://meetings.asco.org/abstracts-presentations/235071</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factors associated with liver cancer in all US participants.</td>
<td>Jing Su</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical features, genomic alterations, and survival outcomes for variant histology urothelial carcinoma.</td>
<td>Bryan Schneider, Nabil Adra, Jennifer King</td>
<td></td>
<td>Abstract # e16549</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/231950">https://meetings.asco.org/abstracts-presentations/231950</a></td>
</tr>
<tr>
<td>Real-world clinical and toxicity outcomes in older Veterans with metastatic renal cell carcinoma (mRCC) treated with front-line systemic therapy.</td>
<td>Jennifer King</td>
<td></td>
<td>Abstract # e16525</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/231919">https://meetings.asco.org/abstracts-presentations/231919</a></td>
</tr>
<tr>
<td>Unraveling the role of CTLA-4 variants in acute kidney injury after ICI treatments.</td>
<td>Jing Su</td>
<td></td>
<td>Abstract # e14682</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/235066">https://meetings.asco.org/abstracts-presentations/235066</a></td>
</tr>
<tr>
<td>Outcomes in STK11-, KEAP1-, and KRAS-mutant lung squamous cell carcinoma (L SCC) with use of immune checkpoint inhibitors (ICIs).</td>
<td>Julian A. Marin-Acevedo, Misty Shields, Nasser Hanna</td>
<td></td>
<td>Abstract # e20504</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/232262">https://meetings.asco.org/abstracts-presentations/232262</a></td>
</tr>
<tr>
<td>Updated safety and efficacy analysis comparing elderly vs nonelderly patients treated with consolidation nivolumab or nivolumab plus ipilimumab after chemoradiation for unresectable stage III NSCLC from the BTCRC LUN 16-081 clinical trial.</td>
<td>Nasser Hanna, Greg Durm</td>
<td></td>
<td>Abstract # e13770</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/237348">https://meetings.asco.org/abstracts-presentations/237348</a></td>
</tr>
<tr>
<td>KeratoIoma and ocular dryness as predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.</td>
<td>Tareq Salous, Jennifer King, Nabil Adra</td>
<td></td>
<td>Abstract # e17028</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/230907">https://meetings.asco.org/abstracts-presentations/230907</a></td>
</tr>
<tr>
<td>Neuroendocrine features in small cell lung cancer (SCLC) and associations with platinum-sensitivity, metastatic tropism, and overall survival.</td>
<td>Julian A. Marin-Acevedo, Misty Shields, Mya Tran</td>
<td></td>
<td>Abstract # e20113</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233447">https://meetings.asco.org/abstracts-presentations/233447</a></td>
</tr>
<tr>
<td>The survival benefits and the risk of severe renal injury of immune checkpoint inhibitors in patients with cancer: The real-world evidence from the National Clinical Cohort Collaborative (NCC).</td>
<td>Tyler Shugg, Shadia Jalal, Jing Su</td>
<td></td>
<td>Abstract # e24142</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/233563">https://meetings.asco.org/abstracts-presentations/233563</a></td>
</tr>
<tr>
<td>Characterization of novel compounds that directly bind to and inactivate the HPV E6 protein for treatment of HPV-associated cervical and oropharyngeal cancers.</td>
<td>Anne Rietz, Elliot Androphy</td>
<td></td>
<td>Abstract # e15122</td>
<td><a href="https://meetings.asco.org/abstracts-presentations/235563">https://meetings.asco.org/abstracts-presentations/235563</a></td>
</tr>
</tbody>
</table>